Compare Kimberly Clark Corp (KMB) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Repligen Corporation Common Stock — how do they compare? Kimberly Clark Corp trades at $100.35 (market cap $32.69B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Kimberly Clark Corp is far larger — about 2.9× Repligen Corporation Common Stock's market cap, and Kimberly Clark Corp pays a 5.21% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 94 Days and Repligen Corporation Common Stock for 0 Days on average.
| KMB | RGEN | |
|---|---|---|
Market Cap | $32.69B | $11.14B |
Volume | 6,331,515 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $194.57 |
52-Week Low | $93.05 | $102.87 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $38.25B | $11.02B |
Dividend Yield | 5.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $99.41, up 0.65% on the day, showing modest recovery after recent declines. The stock faces technical headwinds with bearish moving averages and overbought RSI signals, while fundamentals reveal mixed results with Q2 2026 earnings miss but strong profitability margins. Recent executive transitions and the pending Kenvue acquisition dominate news flow, creating uncertainty around the company's strategic direction and cash flow sustainability.
KMB presents a complex investment case with a 5.16% dividend yield and 54-year dividend growth streak offset by acquisition risks and cash flow concerns. Analyst consensus at $117.25 suggests 18% upside potential, but the stock requires careful monitoring of integration execution and dividend coverage metrics amid changing leadership.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
